AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
Growthavutometinib potassium and defactinib hydrochloride
NDAORALCAPSULE, TABLETPriority Review
Approved
May 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
5/8 — Partial
Priority Review
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) (avutometinib potassium and defactinib hydrochloride) by Verastem Oncology is mek1 inhibitor. Approved for ovarian cancer. First approved in 2025.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVMAPKI FAKZYNJA CO-PACK is a copackaged oral combination of avutometinib (MEK1/2 inhibitor) and defactinib (FAK/Pyk2 inhibitor) approved for ovarian cancer treatment. The combination targets the RAS/MAPK pathway while simultaneously inhibiting focal adhesion kinase signaling to enhance anti-tumor activity in KRAS-mutant and other difficult-to-treat ovarian cancers. This dual-mechanism approach represents a precision oncology strategy designed to overcome single-agent resistance.
Growth16.1 years to LOE
Recent 2025 approval positions this as a growth-stage product with expanding commercial infrastructure; Medical Affairs and field teams are actively scaling to support market penetration in a niche but high-value oncology segment.
Mechanism of Action
MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents phosphorylation of MEK1/2 by RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Avutometinib inhibited MEK1/2 and ERK1/2 phosphorylation and proliferation of tumor cell lines…
Indications (1)
Worked on AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) at Verastem Oncology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.